TABLE 2.

Comparison of clinical symptom scores.

	Drug group (n = 181)				Control group (n = 186)
	Baseline a	3 months later	P-value	D-value b	Baseline	3 months later	P-value	D-value b	P-value c
Cough	6.18 ± 2.00	3.03 ± 1.64 d	<0.001	3.15 ± 1.88	6.06 ± 1.84	3.76 ± 1.70	<0.001	2.31 ± 1.70	<0.001
Expectoration	7.36 ± 2.35	4.57 ± 2.89 d	<0.001	2.78 ± 2.53	7.21 ± 2.28	6.05 ± 2.85	<0.001	1.16 ± 2.23	<0.001
Expectoration volume	5.20 ± 2.40	2.62 ± 2.17 d	<0.001	2.59 ± 2.04	5.44 ± 2.46	3.10 ± 2.18	<0.001	2.33 ± 1.95	0.251
Total cough score	18.75 ± 5.67	10.23 ± 5.77 d	<0.001	8.52 ± 4.71	18.71 ± 5.35	12.90 ± 5.44	<0.001	5.81 ± 4.09	<0.001
Dyspnea	2.32 ± 2.34	1.03 ± 1.56	<0.001	1.29 ± 2.08	2.19 ± 2.19	1.26 ± 1.70	<0.001	0.94 ± 1.71	0.180
Hemoptysis	1.11 ± 2.00	0.36 ± 1.17	<0.001	0.75 ± 2.10	1.39 ± 1.98	0.47 ± 1.22	<0.001	0.92 ± 1.87	0.191
Chest pain	0.60 ± 1.43	0.23 ± 0.92	0.003	0.36 ± 1.17	0.77 ± 1.52	0.26 ± 0.95	<0.001	0.52 ± 1.47	0.131
Total symptom score	22.77 ± 7.06	11.85 ± 7.05 d	<0.001	10.92 ± 5.89	23.06 ± 6.11	14.89 ± 6.35	<0.001	8.18 ± 4.77	<0.001

Data are presented as mean ± SD except as otherwise noted.

^aThere were no statistical differences in all the clinical symptom scores between the two groups during exacerbation (p > 0.05).

^b D-value, difference value, the difference between baseline and 3 months later.

^cThe p-value of the d-value between two groups.

^dThere were statistical differences between the two groups 3 months later (p < 0.05).